Natera, Inc. (NASDAQ:NTRA) Receives Consensus Rating of “Buy” from Analysts

Natera, Inc. (NASDAQ:NTRA) has been given a consensus recommendation of “Buy” by the fifteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Fifteen equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have covered the stock in the last year is $120.07.

A number of analysts have issued reports on NTRA shares. Stephens reissued an “overweight” rating and issued a $125.00 target price on shares of Natera in a research report on Friday, August 9th. Piper Sandler reissued an “overweight” rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. Canaccord Genuity Group raised their target price on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. Robert W. Baird boosted their price target on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Finally, StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 37,500 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $108.10, for a total value of $4,053,750.00. Following the completion of the sale, the chief executive officer now owns 213,351 shares in the company, valued at $23,063,243.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Natera news, CEO Steven Leonard Chapman sold 37,500 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $108.10, for a total transaction of $4,053,750.00. Following the transaction, the chief executive officer now directly owns 213,351 shares in the company, valued at $23,063,243.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Burkes Brophy sold 4,983 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $108.37, for a total value of $540,007.71. Following the completion of the transaction, the chief financial officer now owns 75,059 shares of the company’s stock, valued at approximately $8,134,143.83. The disclosure for this sale can be found here. In the last three months, insiders have sold 91,221 shares of company stock valued at $10,206,842. 7.60% of the stock is owned by company insiders.

Institutional Trading of Natera

Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. SG Americas Securities LLC raised its holdings in shares of Natera by 1,073.1% in the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after purchasing an additional 60,127 shares during the period. Thematics Asset Management increased its position in shares of Natera by 3.1% in the fourth quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock worth $5,652,000 after acquiring an additional 2,738 shares in the last quarter. Crestline Management LP raised its stake in shares of Natera by 16.0% in the 4th quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock valued at $4,076,000 after acquiring an additional 8,997 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Natera by 15.1% during the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after acquiring an additional 9,781 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its holdings in shares of Natera by 289.7% during the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock valued at $53,258,000 after acquiring an additional 632,047 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Stock Up 0.0 %

Shares of NASDAQ NTRA opened at $127.13 on Friday. The stock has a market cap of $15.61 billion, a PE ratio of -40.75 and a beta of 1.53. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. Natera has a 12-month low of $36.90 and a 12-month high of $132.01. The company has a 50-day moving average of $114.12 and a 200 day moving average of $105.05.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.97) EPS. As a group, sell-side analysts predict that Natera will post -1.96 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.